Fig 1: FN1 rescues NNMT‐driven tumor progression. (A, B) Effects of exogenous recombinant FN1 protein and shFN1 on the migration and invasion. (C, D) Quantification of migrated and invaded cells. (E) IC50 values of the PF‐9366 in OS‐RC‐2 Mock and NNMT‐KO cells. (F) FN1 mRNA levels in OS‐RC‐2 cells treated with PF‐9366. (G) FN1 protein levels in OS‐RC‐2 cells after PF‐9366 treatment. (H) Effects of NNMT‐KO in OS‐RC‐2 cells on tumor growth (n = 9 per group), (I) tumor mass (n = 9 per group, tumor mass = mass of tumor‐bearing renal − mass of contralateral renal), (J) number of lung metastases (n = 9 per group), and (K) relative body weight of mice (n = 9 per group). (L) Representative H&E staining of renal and lung tissues. (M) Representative FN1 staining of renal tissues by IHC (left panel), and quantification of the immunoreactive score (right panel, n = 9 per group). Significance was assessed using one‐way ANOVA followed by Dunnett's multiple comparisons test (C, D, F), two‐way ANOVA followed by Sidak's multiple comparisons test (K), or Student's t‐test (I, J, M). (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). H&E, hematoxylin and eosin; IHC, immunohistochemistry; PF‐9366, methionine adenosyltransferase 2A (Mat2A) inhibitor (HY‐107778, MCE).